Association between Single Nucleotide Polymorphisms (SNPs) and Toxicity of Advanced Non-Small-Cell Lung Cancer Patients Treated with Chemotherapy

New therapeutic approaches are being developed based on the findings that several genetic abnormalities underlying non-small-cell lung cancer (NSCLC) could influence chemosensitivity. In this study, we assessed whether polymorphisms in genes of nucleotide excision repair (NER) pathway, including ERCC5, ERCC6, MMS19L, CCNH, XPC, RRM1, can affect the tolerability of platinum-based chemotherapy in NSCLC patients. We used AllGloTM probe to assess genotyping and polymorphisms in 388 stage IIIB and IV NSCLC patients treated with platinum-based chemotherapy. MMS19L might be associated with the adverse events of chemotherapy in NSCLC, especially for all grade leucopenia (P = 0.020), all grade jaundice (P = 0.037) and all grade creatinine increasing (P = 0.013). In terms of grade 3/4 adverse events, MMS19L was related with total grade 3/4 adverse events (P = 0.024) and grade 3/4 thrombocytopenia (P = 0.035), while RRM1 was related with total grade 3/4 adverse events (P = 0.047) and grade 3/4 vomiting (P = 0.046). ERCC5 was related with more infection (P = 0.017). We found that some SNPs in NER pathway genes were correlated with toxicity treated with double chemotherapy in advanced NSCLC patients, especially for SNPs of MMS19L, RRM1 and ERCC5.

[1]  L. Mullenders,et al.  The role of XPC: implications in cancer and oxidative DNA damage. , 2011, Mutation research.

[2]  S. Lheureux,et al.  Evaluation of current practice: management of chemotherapy-related toxicities , 2011, Anti-cancer drugs.

[3]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[4]  L. Mullenders,et al.  UV-induced photolesions elicit ATR-kinase-dependent signaling in non-cycling cells through nucleotide excision repair-dependent and -independent pathways , 2011, Journal of Cell Science.

[5]  Y. Hinoda,et al.  Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. , 2010, Pharmacogenomics.

[6]  C. Punt,et al.  Regarding: ‘Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array’ , 2010, British Journal of Cancer.

[7]  W. Au,et al.  Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. , 2010, International journal of hygiene and environmental health.

[8]  Yi Wang,et al.  Association of XPD Polymorphisms with Severe Toxicity in Non–Small Cell Lung Cancer Patients in a Chinese Population , 2009, Clinical Cancer Research.

[9]  Jayne Tierney,et al.  Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Tan,et al.  XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. , 2008, Lung cancer.

[11]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Radinsky,et al.  Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models , 2008 .

[13]  B. Ning,et al.  A variant of the Cockayne syndrome B gene ERCC6 confers risk of lung cancer , 2008, Human mutation.

[14]  G. Scagliotti,et al.  Prospective Assessment of XPD Lys751Gln and XRCC1 Arg399Gln Single Nucleotide Polymorphisms in Lung Cancer , 2007, Clinical Cancer Research.

[15]  G. Bepler,et al.  RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Errol C Friedberg,et al.  Identification of MMS19 domains with distinct functions in NER and transcription. , 2006, DNA repair.

[17]  Stephen J Chanock,et al.  Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer , 2006, Expert review of molecular diagnostics.

[18]  E. Guinó,et al.  Polymorphisms in Genes of Nucleotide and Base Excision Repair: Risk and Prognosis of Colorectal Cancer , 2006, Clinical Cancer Research.

[19]  高橋 聡,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v3.0による胃癌術後合併症の解析 , 2006 .

[20]  D. Campa,et al.  Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. , 2006, Carcinogenesis.

[21]  D. Neuberg,et al.  Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non–Small Cell Lung Cancer Patients , 2005, Clinical Cancer Research.

[22]  D. Neuberg,et al.  XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[24]  R. Ramlau,et al.  Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Bernstein,et al.  DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. , 2002, Mutation research.

[26]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[27]  H. Bartelink,et al.  DNA‐adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy , 2000, International journal of cancer.

[28]  D W Nebert,et al.  Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. , 1996, DNA and cell biology.

[29]  David O. Morgan,et al.  A novel cyclin associates with M015/CDK7 to form the CDK-activating kinase , 1994, Cell.